[go: up one dir, main page]

MX2020005660A - Uso de un agonista de kor en combinacion con un agonista de mor para preparar medicamentos para tratar el dolor. - Google Patents

Uso de un agonista de kor en combinacion con un agonista de mor para preparar medicamentos para tratar el dolor.

Info

Publication number
MX2020005660A
MX2020005660A MX2020005660A MX2020005660A MX2020005660A MX 2020005660 A MX2020005660 A MX 2020005660A MX 2020005660 A MX2020005660 A MX 2020005660A MX 2020005660 A MX2020005660 A MX 2020005660A MX 2020005660 A MX2020005660 A MX 2020005660A
Authority
MX
Mexico
Prior art keywords
agonist
combination
kor
treating pain
mor
Prior art date
Application number
MX2020005660A
Other languages
English (en)
Inventor
Guoqing Cao
Lianshan Zhang
Changyong Yang
Xiaoxing Huang
Original Assignee
Jiangsu Hengrui Medicine Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Ltd filed Critical Jiangsu Hengrui Medicine Ltd
Publication of MX2020005660A publication Critical patent/MX2020005660A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Anesthesiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se divulga el uso de un agonista KOR en combinación con un agonista MOR en la preparación de un medicamento para tratar el dolor. El agonista KOR se selecciona de un compuesto como se muestra en la fórmula general (I), y el agonista MOR se selecciona de un compuesto como se muestra en la fórmula general (II), en donde las definiciones de cada sustituyente en la fórmula general (I) y (II) son los mismos que se definen en la descripción. (Ver Fórmula).
MX2020005660A 2017-12-06 2018-12-05 Uso de un agonista de kor en combinacion con un agonista de mor para preparar medicamentos para tratar el dolor. MX2020005660A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201711272869 2017-12-06
PCT/CN2018/119313 WO2019109937A1 (zh) 2017-12-06 2018-12-05 Kor激动剂与mor激动剂联合在制备治疗疼痛的药物中的用途

Publications (1)

Publication Number Publication Date
MX2020005660A true MX2020005660A (es) 2020-08-20

Family

ID=66751289

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020005660A MX2020005660A (es) 2017-12-06 2018-12-05 Uso de un agonista de kor en combinacion con un agonista de mor para preparar medicamentos para tratar el dolor.

Country Status (11)

Country Link
US (1) US11471503B2 (es)
EP (1) EP3714882A4 (es)
JP (1) JP2021505547A (es)
KR (1) KR20200096787A (es)
CN (1) CN111065390B (es)
AU (1) AU2018380173A1 (es)
BR (1) BR112020010429A2 (es)
CA (1) CA3083028A1 (es)
MX (1) MX2020005660A (es)
TW (1) TW201924681A (es)
WO (1) WO2019109937A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019020691A2 (pt) * 2017-04-14 2020-05-12 Jiangsu Hengrui Medicine Co., Ltd. Composição farmacêutica contendo agonista do mor e agonista do kor, e usos da mesma
WO2020147848A1 (zh) * 2019-01-17 2020-07-23 上海海雁医药科技有限公司 三环取代的氧杂螺环衍生物、其制法与医药上的用途
WO2021026492A1 (en) 2019-08-07 2021-02-11 Humanwell Pharmaceutical US Kappa opioid receptor peptide amide agonists
CN113493490B (zh) * 2020-04-03 2024-03-12 成都诺和晟泰生物科技有限公司 一种合成肽酰胺类化合物及其在医药领域的用途
WO2021262173A1 (en) 2020-06-25 2021-12-30 Humanwell Pharmaceutical US Peptides for treatment of medical disorders
CN114269738B (zh) * 2020-08-10 2023-09-29 成都苑东生物制药股份有限公司 一种mor受体激动剂化合物、制备方法及其用途
CN112694485B (zh) * 2020-09-10 2023-04-07 四川海品信医药科技有限公司 一种阿片受体激动剂噻吩类化合物及其制备方法
CN113995733B (zh) * 2021-09-18 2023-08-22 中国人民解放军军事科学院军事医学研究院 一种噻吩诺啡缓释药物组合物及其制备方法和其用途
CN115317453A (zh) * 2022-09-01 2022-11-11 广东嘉博制药有限公司 一种缓释微球制剂及其制备方法与用途
CN118994123B (zh) * 2024-10-23 2025-02-14 江苏恒瑞医药股份有限公司 制备9-(吡啶-2-基)-6-氧杂螺[4.5]癸烷衍生物的方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5244810B2 (ja) * 2006-11-10 2013-07-24 カラ セラピューティクス インコーポレイテッド 合成ペプチドアミド
US8906859B2 (en) 2006-11-10 2014-12-09 Cera Therapeutics, Inc. Uses of kappa opioid synthetic peptide amides
US7842662B2 (en) * 2006-11-10 2010-11-30 Cara Therapeutics, Inc. Synthetic peptide amide dimers
PT3290415T (pt) 2011-03-23 2021-03-29 Trevena Inc Ligandos de recetores opioides e métodos de utilização e fabrico dos mesmos
KR101773331B1 (ko) * 2012-03-05 2017-08-31 닥터 레디스 레보러터리즈 리미티드 카파 오피오이드 수용체(κor) 작용제인 치환된 헤테로시클릭 아세트아미드
US20160250277A1 (en) 2013-10-28 2016-09-01 Cara Therapeutics, Inc. Peripheral kappa opioid receptor agonists for preventing, inhibiting or treating nausea and vomiting
WO2016073443A2 (en) 2014-11-05 2016-05-12 Cara Therapeutics, Inc. Peripheral kappa opioid receptor agonists for hard tissue pain
ES2772689T3 (es) * 2015-10-15 2020-07-08 Jiangsu Hengrui Medicine Co Derivado de oxa espiro, método de preparación del mismo y aplicaciones del mismo en medicamentos
CA3025710A1 (en) * 2016-06-07 2017-12-14 Jiangsu Hengrui Medicine Co., Ltd. Phenyl propanamide derivative, and manufacturing method and pharmaceutical application thereof
WO2018103624A1 (zh) * 2016-12-06 2018-06-14 江苏恒瑞医药股份有限公司 一种κ阿片受体激动剂在制备治疗法尼醇X受体激动剂引起的瘙痒的药物中的用途
BR112019020691A2 (pt) * 2017-04-14 2020-05-12 Jiangsu Hengrui Medicine Co., Ltd. Composição farmacêutica contendo agonista do mor e agonista do kor, e usos da mesma

Also Published As

Publication number Publication date
RU2020115687A (ru) 2022-01-11
EP3714882A1 (en) 2020-09-30
BR112020010429A2 (pt) 2020-11-24
US20200368309A1 (en) 2020-11-26
WO2019109937A1 (zh) 2019-06-13
EP3714882A4 (en) 2021-09-01
AU2018380173A1 (en) 2020-05-21
CA3083028A1 (en) 2019-06-13
US11471503B2 (en) 2022-10-18
JP2021505547A (ja) 2021-02-18
TW201924681A (zh) 2019-07-01
CN111065390B (zh) 2023-01-24
KR20200096787A (ko) 2020-08-13
RU2020115687A3 (es) 2022-01-31
CN111065390A (zh) 2020-04-24

Similar Documents

Publication Publication Date Title
MX2020005660A (es) Uso de un agonista de kor en combinacion con un agonista de mor para preparar medicamentos para tratar el dolor.
GEP20186933B (en) Substituted dihydroisoquinoline compounds
PH12019550224A1 (en) Antitumoral compounds
NZ736665A (en) Heterocyclic amides as kinase inhibitors
MX2016006432A (es) Tetrahidro-benzodiazepinonas.
GEP20197011B (en) Heteroaryl compounds for kinase inhibition
GEP20186887B (en) Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
EA202192151A1 (ru) Применение пиразолпиримидиновых производных для лечения нарушений, связанных с pi3k
MY188447A (en) Indazole compounds as fger kinase inhibitor, preparation and use thereof
UA118259C2 (uk) Гетероциклічні аміди як інгібітори кінази
MX381994B (es) Inhibidor de janus quinasa.
PH12016501702B1 (en) Pyrazole amide derivative
TN2015000519A1 (en) Small molecule inhibitors of fibrosis
SA519402288B1 (ar) مركب بيريميدين واستخداماته الصيدلانية
GEP201706725B (en) Compounds and compositions as inhibitors of mek
AU2015211852A1 (en) Heterocyclic sulfonamide derivative and medicine comprising same
AU2015352440B2 (en) Compounds
PH12015501588A1 (en) Compounds and methods for treating bacterial infections
PH12018501181A1 (en) Phenyl derivatives as cannabinoid receptor 2 agonists
MX2019010950A (es) Composicion de fotosensibilizador que contiene fenalen-1-ona, compuesto de fenalen-1-ona, asi como su uso.
EP3492468A4 (en) HETEROCYCLIC COMPOUND AS A JAK INHIBITOR, SALTS AND THERAPEUTIC USE THEREOF
EA201691566A1 (ru) Применение производных пиридазина для предупреждения или лечения атаксического синдрома
MX382092B (es) Compuestos heterocíclicos para el tratamiento de enfermedades.
EA033423B1 (ru) Циклопропанбензофуранилпиридопиразиндионы
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы